| scholarly article | Q13442814 |
| P50 | author | Liping X Zhou | Q96239407 |
| P2093 | author name string | Troy Smith | |
| Gang Liu | |||
| B Barry Touré | |||
| Raviraj Kulathila | |||
| Simon van der Plas | |||
| Trixie Wagner | |||
| Xiaoling Xie | |||
| Michael D Jones | |||
| Ming Xu | |||
| Raymond Pagliarini | |||
| Remi Terranova | |||
| Young Shin Cho | |||
| Brant Firestone | |||
| Joseph D Growney | |||
| Ina Dix | |||
| Pascal D Fortin | |||
| John Giraldes | |||
| Julian R Levell | |||
| Kelly Slocum | |||
| Viraj Tyagi | |||
| Ty Gould | |||
| Fallon Lin | |||
| Arne Mueller | |||
| Fan S Yang | |||
| Gregg Chenail | |||
| Julia Dooley | |||
| Thomas Caferro | |||
| P2860 | cites work | Cancer-associated IDH1 mutations produce 2-hydroxyglutarate | Q24320239 |
| Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway | Q27666212 | ||
| Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase | Q27678755 | ||
| New IDH1 mutant inhibitors for treatment of acute myeloid leukemia | Q27702240 | ||
| An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. | Q27852141 | ||
| IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype | Q29617457 | ||
| Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo | Q33630257 | ||
| Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity | Q34394153 | ||
| A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. | Q36446183 | ||
| What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer | Q36832167 | ||
| Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities | Q38116645 | ||
| CNS drug design: balancing physicochemical properties for optimal brain exposure | Q38286160 | ||
| Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity | Q38993122 | ||
| Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule | Q41906201 | ||
| Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. | Q55052388 | ||
| Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer | Q88187482 | ||
| P433 | issue | 2 | |
| P921 | main subject | allosteric inhibitor | Q70361704 |
| P304 | page(s) | 151-156 | |
| P577 | publication date | 2016-12-16 | |
| P1433 | published in | ACS Medicinal Chemistry Letters | Q2819061 |
| P1476 | title | Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1. | |
| P478 | volume | 8 |
| Q42371843 | Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays |
| Q50033966 | Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies. |
| Q48007877 | Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. |
| Q64974414 | Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics. |
| Q52590501 | Novel Insights for Inhibiting Mutant Heterodimer IDH1wt-R132H in Cancer: An In-Silico Approach. |
| Q90403028 | Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors |
Search more.